Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Britain Courts Anthropic Amid US Defense Department Dispute 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
SAN ANTONIO, Nov. 15, 2016 -- bioAffinity Technologies announced that the government of the Hong Kong Special Administrative Region has awarded a Certificate of Grant of Standard Patent for the Company’s proprietary CyPath© technology for the early detection of lung cancer.
The Hong Kong patent, titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP),” grants protection to 2030 for bioAffinity’s platform test for early cancer detection. bioAffinity’s intellectual property (IP) portfolio now consists of 43 awarded patents in 22 countries.
bioAffinity’s porphyrin-based CyPath© bio-label preferentially binds to cancer cells, giving them a distinctive fluorescence that is detectable and measurable by an imaging system. CyPath© Lung, bioAffinity’s initial product, is designed to be a highly accurate, non-invasive, early-stage lung cancer diagnostic for use by those at risk for lung cancer.
“Lung cancer is the leading cause of cancer deaths worldwide, and as much as 85 percent of lung cancers are attributable to smoking,” bioAffinity President and CEO Maria Zannes said. “With an estimated 370 million smokers in China, Hong Kong and Japan, our technology can have a significant positive impact on early detection and more effective treatment of the disease in Asia, the world’s largest market. We are pleased to add the Hong Kong patent to our existing patents in China and Japan.”
bioAffinity is focused on the commercialization of accurate, non-invasive diagnostics and life-saving targeted therapeutics for multiple cancers. CyPath© Lung is a simple and cost-effective diagnostic, which will make it particularly effective in countries with large populations and a broad demographic.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The Company develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas Health Science Center at San Antonio through a collaborative research agreement. The Company’s platform technology will be developed to diagnose, monitor and treat many cancers.
Contact: Maria Zannes, 505.400.9747
